Higher expression of circulating miR‑182 as a novel biomarker for breast cancer

Wang,Ping‑Yu; Gong,Hai‑Tao; Li,Bao‑Feng; Lv,Chun‑Lei; Wang,Huan‑Tai; Zhou,Hui‑Hui; Li,Xin‑Xin; Xie,Shu‑Yang; Jiang,Bao‑Fa

doi:10.3892/ol.2013.1593

Higher expression of circulating miR‑182 as a novel biomarker for breast cancer

Authors:
- Ping‑Yu Wang
- Hai‑Tao Gong
- Bao‑Feng Li
- Chun‑Lei Lv
- Huan‑Tai Wang
- Hui‑Hui Zhou
- Xin‑Xin Li
- Shu‑Yang Xie
- Bao‑Fa Jiang
View Affiliations

Affiliations: School of Public Health, Shandong University, Jinan, Shandong 250012, P.R. China, Laiyang Central Hospital of Weifang Medical College, Yantai, Shandong 264000, P.R. China, Shandong China Traditional Medical Affiliated Hospital, Jinan, Shandong 250012, P.R. China, Department of Pathology, Affiliated Yuhuangding Hospital, Medical College of Qingdao University, Yantai, Shandong 264000, P.R. China, Key Laboratory of Tumour Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Key Laboratory of Tumour Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
Published online on: September 24, 2013 https://doi.org/10.3892/ol.2013.1593
Pages: 1681-1686

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs), present in the serum in a stable and reproducible manner, may be used as biomarkers for various diseases. Few studies have previously investigated circulating miRNAs in the peripheral blood of breast cancer (BC) patients. To identify the role of serum miR‑182 levels in BC, the present study detected miR‑182 levels in the serum of 46 BC patients and 58 controls, by quantitative PCR. The results showed that the serum miR‑182 levels in BC patients were significantly higher compared with the serum of healthy controls (P<0.01). The miR‑182 was also overexpressed in the BC tissues compared with the para‑carcinoma tissues. Furthermore, the serum levels of miR‑182 in the estrogen receptor (ER)‑positive patients were considerably lower compared with those in the ER‑negative patients. The serum levels of miR‑182 in the progesterone receptor (PR)‑positive patients were also found to be lower compared with those in the PR‑negative patients. The current study highlights results consistent with miR‑182 as a novel and valuable biomarker for the diagnosis of BC.

View Figures

View References

1	Sariego J: Breast cancer in the young patient. Am Surg. 76:1397–1400. 2010.
2	Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 9(Suppl 2): S73–S81. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
4	Stefani G and Slack FJ: Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 9:219–230. 2008. View Article : Google Scholar : PubMed/NCBI
5	Di Leva G, Piovan C, Gasparini P, et al: Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet. 9:e10033112013.PubMed/NCBI
6	Ozgün A, Karagoz B, Bilgi O, Tuncel T, Baloglu H and Kandemir EG: MicroRNA-21 as an indicator of aggressive phenotype in breast cancer. Onkologie. 36:115–118. 2013.PubMed/NCBI
7	Han M, Liu M, Wang Y, et al: Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem. 363:427–436. 2012. View Article : Google Scholar : PubMed/NCBI
8	Yu SJ, Hu JY, Kuang XY, et al: MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res. 19:1389–1399. 2013. View Article : Google Scholar : PubMed/NCBI
9	Castilla MÁ, Díaz-Martín J, Sarrió D, et al: MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One. 7:e477092012.PubMed/NCBI
10	Sun X, Qin S, Fan C, Xu C, Du N and Ren H: Let-7: a regulator of the ERα signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep. 29:2079–2087. 2013.PubMed/NCBI
11	Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
12	Hunter MP, Ismail N, Zhang X, et al: Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 3:e36942008. View Article : Google Scholar : PubMed/NCBI
13	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
14	Zhu W, Qin W, Atasoy U and Sauter ER: Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2:892009. View Article : Google Scholar : PubMed/NCBI
15	Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
16	Schrauder MG, Strick R, Schulz-Wendtland R, et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One. 7:e297702012. View Article : Google Scholar : PubMed/NCBI
17	Wu AH, Vigen C, Razavi P, Tseng CC and Stancyzk FZ: Alcohol and breast cancer risk among Asian-American women in Los Angeles County. Breast Cancer Res. 14:R1512012. View Article : Google Scholar : PubMed/NCBI
18	Shrubsole MJ, Gao YT, Dai Q, et al: Passive smoking and breast cancer risk among non-smoking Chinese women. Int J Cancer. 110:605–609. 2004. View Article : Google Scholar : PubMed/NCBI
19	Gammon MD, Eng SM, Teitelbaum SL, et al: Environmental tobacco smoke and breast cancer incidence. Environ Res. 96:176–185. 2004. View Article : Google Scholar : PubMed/NCBI
20	Chiang CH, Hou MF and Hung WC: Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta. 1830:3067–3076. 2013.
21	Krishnan K, Steptoe AL, Martin HC, et al: MicroRNA-182-5p targets a network of genes involved in DNA repair. RNA. 19:230–242. 2013. View Article : Google Scholar : PubMed/NCBI
22	Cui X, Schiff R, Arpino G, Osborne CK and Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 23:7721–7735. 2005. View Article : Google Scholar : PubMed/NCBI
23	Diaz NM: Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control. 8:415–418. 2001.PubMed/NCBI
24	Heneghan HM, Miller N, Lowery AJ, Sweeney KJ and Kerin MJ: MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol. 2009:9502012009.PubMed/NCBI
25	Xi Y, Nakajima G, Gavin E, et al: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 13:1668–1674. 2007. View Article : Google Scholar : PubMed/NCBI
26	Li J, Smyth P, Flavin R, et al: Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 7:362007. View Article : Google Scholar
27	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
28	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
29	Mattie MD, Benz CC, Bowers J, et al: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 5:242006. View Article : Google Scholar
30	Zhong S, Chen Z, Xu J, Li W and Zhao J: Pre-mir-27a rs895819 polymorphism and cancer risk: a meta-analysis. Mol Biol Rep. 40:3181–3186. 2013. View Article : Google Scholar : PubMed/NCBI
31	Pastrello C, Polesel J, Della Puppa L, Viel A and Maestro R: Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis. 31:2124–2126. 2010. View Article : Google Scholar : PubMed/NCBI
32	Linhares JJ, Azevedo M Jr, Siufi AA, et al: Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer. BMC Med Genet. 13:1192012. View Article : Google Scholar : PubMed/NCBI
33	Moskwa P, Buffa FM, Pan Y, et al: miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 41:210–220. 2011. View Article : Google Scholar : PubMed/NCBI
34	Guttilla IK and White BA: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI
35	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
36	Liu J, Mao Q, Liu Y, Hao X, Zhang S and Zhang J: Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res. 25:46–54. 2013.PubMed/NCBI
37	Chen W, Cai F, Zhang B, Barekati Z and Zhong XY: The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 34:455–462. 2013. View Article : Google Scholar : PubMed/NCBI
38	Si H, Sun X, Chen Y, et al: Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 139:223–229. 2013. View Article : Google Scholar : PubMed/NCBI
39	Osborne CK, Schiff R, Arpino G, Lee AS and Hilsenbeck VG: Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 14:458–465. 2005. View Article : Google Scholar
40	Faheem M, Mahmood H, Khurram M, Qasim U and Irfan J: Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancermedicalscience. 6:2832012.